Antioxidant Flavonoid Diosmetin Is Cardio-Protective in a Rat model of Myocardial Infarction induced by Beta 1-Adrenergic Receptor Activation

Abstract

Myocardial infarction (MI), is a common and life-threatening manifestation of ischemic heart diseases. The most important risk factor for MI is hypertension. Flavonoids have been found to be efficacious in ischemic heart diseases by alleviating oxidative stress and beta-1 adrenergic activation but the mechanistic link is not clear. We hypothesized that antioxidant flavonoid diosmetin is cardio-protective in a rat model of MI induced by beta 1-adrenergic receptor activation. To test this hypothesis, we evaluated the cardioprotective potential of diosmetin on isoproterenol-induced myocardial infarction in rats by performing lead II electrocardiography (ECG), cardiac biomarkers including troponin I and creatinine kinase by using biolyzer 100, as well as histopathological analysis. We found that diosmetin (1 and 3 mg/kg) attenuated isoproterenol-induced elevation in T-wave and deep Q-wave on the ECG, as well as heart to body weight ratio (0.53 ± 0.01 vs. 0.34 ± 0.02, p< 0.001), and infarction size (55 ± 3.16 vs 13.33 ± 1.83 p< 0.001). In addition, pretreatment with diosmetin attenuated the isoproterenol-induced increase in serum troponin I (0.68 ± 0.012 vs 0.310 ± 0.0115, p< 0.001). These results demonstrate that flavonoid diosmetin may provide therapeutic benefit in myocardial infarction. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.